أعرض في EDS

Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)

التفاصيل البيبلوغرافية
العنوان: Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
المؤلفون: Isabel Muehlen-Bartmer, Robert E. Ratner, Paramesh Shamanna, Kyung Wan Min, Patrick Miossec, Tianyue Zhou, Julio Rosenstock, Gabor Boka, Markolf Hanefeld
المصدر: Journal of Diabetes and its Complications. 28(3):386-392
بيانات النشر: Elsevier BV, 2014.
سنة النشر: 2014
مصطلحات موضوعية: Blood Glucose, Male, Internationality, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, Gastroenterology, chemistry.chemical_compound, Endocrinology, Sulfonylurea, Medicine, Insulin, Middle Aged, Postprandial Period, Metformin, Postprandial, Treatment Outcome, Anesthesia, Drug Therapy, Combination, Female, medicine.drug, Adult, medicine.medical_specialty, Lixisenatide, Hypoglycemia, Placebo, Double-Blind Method, Internal medicine, Internal Medicine, Humans, Hypoglycemic Agents, Glycemic, Aged, Glycated Hemoglobin, GLP-1 receptor agonists, Dose-Response Relationship, Drug, business.industry, Type 2 Diabetes Mellitus, nutritional and metabolic diseases, medicine.disease, Glucagon, Sulfonylurea Compounds, chemistry, Diabetes Mellitus, Type 2, business, Peptides
الوصف: AimsTo assess efficacy and safety of lixisenatide once-daily versus placebo in Type 2 diabetes mellitus (T2DM) patients inadequately controlled on sulfonylurea (SU)±metformin.MethodsIn this randomized, double-blind, two-arm, parallel-group, multicenter study, patients received lixisenatide 20μg once-daily or placebo for 24 weeks in a stepwise dose increase on top of SUs±metformin. Primary outcome was change in HbA1c from baseline to Week 24.ResultsLixisenatide provided a significant reduction in HbA1c at Week 24 versus placebo (LS mean: −0.85% vs. −0.10%; p
تدمد: 1056-8727
DOI: 10.1016/j.jdiacomp.2014.01.012
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9dcf072f2a1ba916d27fd2184881ab2Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....b9dcf072f2a1ba916d27fd2184881ab2
قاعدة البيانات: OpenAIRE
الوصف
تدمد:10568727
DOI:10.1016/j.jdiacomp.2014.01.012